Immunotherapies targeting extracellular tau share the premise that interrupting cell-to-cell spread of tau pathology in Alzheimer’s disease (AD) will slow dementia pathogenesis. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.